Global Health Partner third quarter revenue increases 17% to SEK 108.8 million

Global Health Partner AB (STO:GHP):

THIRD QUARTER 2010

· Revenues increased by 17 percent to SEK 108.8 million (93.3)

· The operating result amounted to SEK -4.1 million (-13.1)

· The result before tax amounted to SEK -4.8 million (-12.7)

· The result after tax amounted to SEK -5.0 million (-12.0)

· The result per share amounted to SEK -0.07 (-0.19)

· Organic growth of 15 percent

· Newly opened obesity clinics in Denmark

· Newly opened orthopaedic and gastroenterologic business in Lund

· Arrhythmia new Service Line

JANUARY - SEPTEMBER 2010

· Revenues increased by 16 percent to SEK 407.9 million (352.1)

· The operating result amounted to SEK 15.9 million (-4.3)

· The result before tax amounted to SEK 16.5 million (-5.3)

· The result after tax amounted to SEK 7.5 million (-9.9)

· The result per share amounted to SEK 0.01 (-0.26)

· Organic growth of 15 percent

THE CEO'S COMMENTS The market situation for the existing Swedish clinics is stable, primarily with regard to the outcome of the Swedish Parliamentary elections that resulted in that very few changes are expected in the Swedish County Councils. Continued focus on patient rights, patient safety and transparency in the follow-up of quality in Swedish healthcare favour Global Health Partner's business model and ensure that it will be possible to further profile and market our high quality and cost-effective services.

After a period of turbulence in the Danish hospital service, the situation has now stabilised. We have had a good start for our two Bariatric Centers, which perform obesity operations in Copenhagen and Odense. In Norway the market situation is unfavourable and the volume inflow for spine surgery at the Bergen clinic is unsatisfactory. On the other hand, the demand for obesity operations continues to increase. In other markets the situation is stable and the current clinics are performing in line with our plans, with the exception of a somewhat slower development of volumes for the Bariatric clinic in Prague.

The third quarter is the weakest quarter of the year due to the holiday period in July and August. Compared with the previous year the overall result from the clinics is considerably better. The central development costs continue to be under control, which contributes to a favourable development of the results for the Group as a whole.

During the period two new clinics within the Bariatrics area were started in Denmark. Just after the end of the period, we also acquired the majority of the shares in Stockholm Gastro Center, a business with a very good reputation in the field of medical and surgical gastroenterology including endoscopy, next to our Bariatric clinic at Sophiahemmet. This clinic complements what we have to offer in the gastro area and will contribute with synergies in both the business and the premises. Furthermore, we have started up both gastroenterology and orthopaedics in our clinic in Skåne during the period as a complement to the Bariatrics business. This is one further example of the improvement and expansion that we carry out in the existing clinics.

We see continued good demand in our clinics in the very near future. We will also in time further strengthen our positions in the market, based on the very good medical results that are achieved in our clinics and which amongst other things are documented in the Swedish quality register.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024